Owing to its favourable safety profile, ability to deliver high doses with minimal systemic toxicity, and controlled membrane diffusion-based release, LAmB has been increasingly investigated for direct pulmonary administration, both as prophylaxis and as a treatment for pulmonary aspergillosis (Adler-Moore and Proffitt, 2002; Stone et al., 2016). This evidence concerns the gene GRAMD1B and aspergillosis.